| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Lung cancer.
|
N Engl J Med
|
2008
|
13.49
|
|
2
|
The BATTLE trial: personalizing therapy for lung cancer.
|
Cancer Discov
|
2011
|
7.57
|
|
3
|
Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer.
|
J Clin Invest
|
2006
|
5.73
|
|
4
|
PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib.
|
Cancer Res
|
2007
|
5.45
|
|
5
|
Phase II trial of erlotinib plus concurrent whole-brain radiation therapy for patients with brain metastases from non-small-cell lung cancer.
|
J Clin Oncol
|
2013
|
4.72
|
|
6
|
Prognostic or predictive plasma cytokines and angiogenic factors for patients treated with pazopanib for metastatic renal-cell cancer: a retrospective analysis of phase 2 and phase 3 trials.
|
Lancet Oncol
|
2012
|
4.58
|
|
7
|
Second-line treatment of advanced non-small cell lung cancer.
|
J Thorac Oncol
|
2008
|
3.95
|
|
8
|
Blood-based biomarkers of SU11248 activity and clinical outcome in patients with metastatic imatinib-resistant gastrointestinal stromal tumor.
|
Clin Cancer Res
|
2007
|
3.53
|
|
9
|
An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance.
|
Clin Cancer Res
|
2012
|
3.48
|
|
10
|
Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial.
|
Lancet Oncol
|
2010
|
3.30
|
|
11
|
Effect of KRAS oncogene substitutions on protein behavior: implications for signaling and clinical outcome.
|
J Natl Cancer Inst
|
2012
|
2.79
|
|
12
|
Proteomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including PARP1.
|
Cancer Discov
|
2012
|
2.68
|
|
13
|
Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: efficacy and circulating angiogenic biomarkers associated with therapeutic resistance.
|
J Clin Oncol
|
2009
|
2.52
|
|
14
|
Distinct patterns of cytokine and angiogenic factor modulation and markers of benefit for vandetanib and/or chemotherapy in patients with non-small-cell lung cancer.
|
J Clin Oncol
|
2009
|
2.48
|
|
15
|
Proteomic markers of DNA repair and PI3K pathway activation predict response to the PARP inhibitor BMN 673 in small cell lung cancer.
|
Clin Cancer Res
|
2013
|
2.09
|
|
16
|
Combined vascular endothelial growth factor receptor and epidermal growth factor receptor (EGFR) blockade inhibits tumor growth in xenograft models of EGFR inhibitor resistance.
|
Clin Cancer Res
|
2009
|
2.04
|
|
17
|
Validation of a standardized method for enumerating circulating endothelial cells and progenitors: flow cytometry and molecular and ultrastructural analyses.
|
Clin Cancer Res
|
2009
|
2.00
|
|
18
|
Glioblastoma resistance to anti-VEGF therapy is associated with myeloid cell infiltration, stem cell accumulation, and a mesenchymal phenotype.
|
Neuro Oncol
|
2012
|
1.96
|
|
19
|
Baseline vascular endothelial growth factor concentration as a potential predictive marker of benefit from vandetanib in non-small cell lung cancer.
|
Clin Cancer Res
|
2009
|
1.87
|
|
20
|
Phase II study of recombinant human endostatin in patients with advanced neuroendocrine tumors.
|
J Clin Oncol
|
2006
|
1.86
|
|
21
|
Metronomic chemotherapy enhances the efficacy of antivascular therapy in ovarian cancer.
|
Cancer Res
|
2007
|
1.66
|
|
22
|
Phase 1-2 study of docetaxel plus aflibercept in patients with recurrent ovarian, primary peritoneal, or fallopian tube cancer.
|
Lancet Oncol
|
2011
|
1.65
|
|
23
|
Robust gene expression signature from formalin-fixed paraffin-embedded samples predicts prognosis of non-small-cell lung cancer patients.
|
Clin Cancer Res
|
2011
|
1.59
|
|
24
|
Plasma cytokine and angiogenic factor profiling identifies markers associated with tumor shrinkage in early-stage non-small cell lung cancer patients treated with pazopanib.
|
Cancer Res
|
2010
|
1.58
|
|
25
|
miR-200 Inhibits lung adenocarcinoma cell invasion and metastasis by targeting Flt1/VEGFR1.
|
Mol Cancer Res
|
2010
|
1.54
|
|
26
|
Targeting the angiopoietin/Tie2 pathway: cutting tumor vessels with a double-edged sword?
|
J Clin Oncol
|
2011
|
1.53
|
|
27
|
Upregulated stromal EGFR and vascular remodeling in mouse xenograft models of angiogenesis inhibitor-resistant human lung adenocarcinoma.
|
J Clin Invest
|
2011
|
1.52
|
|
28
|
HIF2alpha cooperates with RAS to promote lung tumorigenesis in mice.
|
J Clin Invest
|
2009
|
1.49
|
|
29
|
Prognostic impact of radiation therapy to the primary tumor in patients with non-small cell lung cancer and oligometastasis at diagnosis.
|
Int J Radiat Oncol Biol Phys
|
2012
|
1.43
|
|
30
|
Reciprocal regulation of c-Src and STAT3 in non-small cell lung cancer.
|
Clin Cancer Res
|
2009
|
1.39
|
|
31
|
Molecular targets for cancer chemoprevention.
|
Nat Rev Drug Discov
|
2009
|
1.38
|
|
32
|
Differential effects of vascular endothelial growth factor receptor-2 inhibitor ZD6474 on circulating endothelial progenitors and mature circulating endothelial cells: implications for use as a surrogate marker of antiangiogenic activity.
|
Clin Cancer Res
|
2005
|
1.33
|
|
33
|
Therapeutic efficacy of endostatin exhibits a biphasic dose-response curve.
|
Cancer Res
|
2005
|
1.33
|
|
34
|
CXCR2 expression in tumor cells is a poor prognostic factor and promotes invasion and metastasis in lung adenocarcinoma.
|
Cancer Res
|
2012
|
1.32
|
|
35
|
Metabolic and functional genomic studies identify deoxythymidylate kinase as a target in LKB1-mutant lung cancer.
|
Cancer Discov
|
2013
|
1.27
|
|
36
|
Vandetanib (ZD6474): an orally available receptor tyrosine kinase inhibitor that selectively targets pathways critical for tumor growth and angiogenesis.
|
Expert Opin Investig Drugs
|
2007
|
1.24
|
|
37
|
Functional characterization of CLPTM1L as a lung cancer risk candidate gene in the 5p15.33 locus.
|
PLoS One
|
2012
|
1.24
|
|
38
|
Aberrant expression of proteins involved in signal transduction and DNA repair pathways in lung cancer and their association with clinical parameters.
|
PLoS One
|
2012
|
1.17
|
|
39
|
Targeted therapies for lung cancer: clinical experience and novel agents.
|
Cancer J
|
2011
|
1.17
|
|
40
|
The SUMO E3-ligase PIAS1 regulates the tumor suppressor PML and its oncogenic counterpart PML-RARA.
|
Cancer Res
|
2012
|
1.11
|
|
41
|
Proteomic profiling identifies pathways dysregulated in non-small cell lung cancer and an inverse association of AMPK and adhesion pathways with recurrence.
|
J Thorac Oncol
|
2010
|
1.08
|
|
42
|
DNA repair biomarker profiling of head and neck cancer: Ku80 expression predicts locoregional failure and death following radiotherapy.
|
Clin Cancer Res
|
2011
|
1.08
|
|
43
|
The association of alternate VEGF ligands with resistance to anti-VEGF therapy in metastatic colorectal cancer.
|
PLoS One
|
2013
|
1.08
|
|
44
|
KDM2A promotes lung tumorigenesis by epigenetically enhancing ERK1/2 signaling.
|
J Clin Invest
|
2013
|
1.07
|
|
45
|
About CD45-/CD31+/CD105+ circulating cells in patients with gynecologic malignancies--letter.
|
Clin Cancer Res
|
2014
|
1.06
|
|
46
|
Endostatin inhibits the vascular endothelial growth factor-induced mobilization of endothelial progenitor cells.
|
Cancer Res
|
2003
|
1.06
|
|
47
|
Increased VEGFR-2 gene copy is associated with chemoresistance and shorter survival in patients with non-small-cell lung carcinoma who receive adjuvant chemotherapy.
|
Cancer Res
|
2011
|
1.05
|
|
48
|
The convergent development of molecular-targeted drugs for cancer treatment and prevention.
|
Clin Cancer Res
|
2007
|
1.04
|
|
49
|
Vascular endothelial growth factor receptor tyrosine kinase inhibitors vandetanib (ZD6474) and AZD2171 in lung cancer.
|
Clin Cancer Res
|
2007
|
1.04
|
|
50
|
Targeting EGFR activity in blood vessels is sufficient to inhibit tumor growth and is accompanied by an increase in VEGFR-2 dependence in tumor endothelial cells.
|
Microvasc Res
|
2008
|
1.03
|
|
51
|
Summary statement: novel agents in the treatment of lung cancer: advances in epidermal growth factor receptor-targeted agents.
|
Clin Cancer Res
|
2006
|
1.03
|
|
52
|
Antitumor activity of a novel STAT3 inhibitor and redox modulator in non-small cell lung cancer cells.
|
Biochem Pharmacol
|
2012
|
1.03
|
|
53
|
Serum signature of hypoxia-regulated factors is associated with progression after induction therapy in head and neck squamous cell cancer.
|
Mol Cancer Ther
|
2010
|
1.03
|
|
54
|
Global evaluation of Eph receptors and ephrins in lung adenocarcinomas identifies EphA4 as an inhibitor of cell migration and invasion.
|
Mol Cancer Ther
|
2012
|
1.01
|
|
55
|
Dual targeting of the vascular endothelial growth factor and epidermal growth factor receptor pathways: rationale and clinical applications for non-small-cell lung cancer.
|
Clin Lung Cancer
|
2007
|
1.01
|
|
56
|
Specific blockade of VEGF and HER2 pathways results in greater growth inhibition of breast cancer xenografts that overexpress HER2.
|
Cell Cycle
|
2008
|
0.98
|
|
57
|
A phase 2 pilot trial of low-dose, continuous infusion, or "metronomic" paclitaxel and oral celecoxib in patients with metastatic melanoma.
|
Cancer
|
2010
|
0.98
|
|
58
|
Positron emission tomography/computed tomography-guided intensity-modulated radiotherapy for limited-stage small-cell lung cancer.
|
Int J Radiat Oncol Biol Phys
|
2011
|
0.97
|
|
59
|
Myeloid biomarkers associated with glioblastoma response to anti-VEGF therapy with aflibercept.
|
Clin Cancer Res
|
2011
|
0.97
|
|
60
|
Vascular endothelial growth factor accelerates compensatory lung growth after unilateral pneumonectomy.
|
Am J Physiol Lung Cell Mol Physiol
|
2006
|
0.96
|
|
61
|
Pharmacodynamic analysis of target inhibition and endothelial cell death in tumors treated with the vascular endothelial growth factor receptor antagonists SU5416 or SU6668.
|
Clin Cancer Res
|
2005
|
0.96
|
|
62
|
Comprehensive biomarker analysis and final efficacy results of sorafenib in the BATTLE trial.
|
Clin Cancer Res
|
2013
|
0.95
|
|
63
|
Synergistic anti-proliferative and pro-apoptotic activity of combined therapy with bortezomib, a proteasome inhibitor, with anti-epidermal growth factor receptor (EGFR) drugs in human cancer cells.
|
J Cell Physiol
|
2008
|
0.94
|
|
64
|
Endothelial progenitor cells contribute to accelerated liver regeneration.
|
J Pediatr Surg
|
2007
|
0.93
|
|
65
|
Vascular endothelial growth factor (VEGF) pathway.
|
J Thorac Oncol
|
2006
|
0.89
|
|
66
|
Farnesyl transferase inhibitors for patients with lung cancer.
|
Clin Cancer Res
|
2004
|
0.89
|
|
67
|
Circulating biomarkers in advanced renal cell carcinoma: clinical applications.
|
Curr Oncol Rep
|
2012
|
0.89
|
|
68
|
A novel therapeutic combination for neuroblastoma: the vascular endothelial growth factor receptor/epidermal growth factor receptor/rearranged during transfection inhibitor vandetanib with 13-cis-retinoic acid.
|
Cancer
|
2010
|
0.87
|
|
69
|
Circulating biomarkers for vascular endothelial growth factor inhibitors in renal cell carcinoma.
|
Cancer
|
2009
|
0.86
|
|
70
|
A high content clonogenic survival drug screen identifies mek inhibitors as potent radiation sensitizers for KRAS mutant non-small-cell lung cancer.
|
J Thorac Oncol
|
2014
|
0.86
|
|
71
|
Genes suppressed by DNA methylation in non-small cell lung cancer reveal the epigenetics of epithelial-mesenchymal transition.
|
BMC Genomics
|
2014
|
0.85
|
|
72
|
Modulation of c-Met signaling and cellular sensitivity to radiation: potential implications for therapy.
|
Cancer
|
2013
|
0.84
|
|
73
|
The tyrosine kinase inhibitor cediranib for non-small cell lung cancer and other thoracic malignancies.
|
J Thorac Oncol
|
2008
|
0.84
|
|
74
|
C-Met inhibitor MK-8003 radiosensitizes c-Met-expressing non-small-cell lung cancer cells with radiation-induced c-Met-expression.
|
J Thorac Oncol
|
2012
|
0.83
|
|
75
|
Emerging antiangiogenic agents in lung cancer.
|
Clin Lung Cancer
|
2006
|
0.83
|
|
76
|
Novel agents in the treatment of lung cancer: Fourth Cambridge Conference.
|
Clin Cancer Res
|
2007
|
0.83
|
|
77
|
Phase II trial of carboplatin, paclitaxel, cetuximab, and bevacizumab followed by cetuximab and bevacizumab in advanced nonsquamous non-small-cell lung cancer: SWOG S0536.
|
J Thorac Oncol
|
2013
|
0.81
|
|
78
|
TGFβ1 Polymorphisms Predict Distant Metastasis-Free Survival in Patients with Inoperable Non-Small-Cell Lung Cancer after Definitive Radiotherapy.
|
PLoS One
|
2013
|
0.78
|
|
79
|
Circulating biomarkers of response to sunitinib in gastroenteropancreatic neuroendocrine tumors: current data and clinical outlook.
|
Mol Diagn Ther
|
2012
|
0.78
|
|
80
|
Inhibition of intra-abdominal adhesion formation with the angiogenesis inhibitor sunitinib.
|
J Surg Res
|
2007
|
0.77
|
|
81
|
Summary statement novel agents in the treatment of lung cancer: Fifth Cambridge Conference assessing opportunities for combination therapy.
|
J Thorac Oncol
|
2008
|
0.76
|
|
82
|
Corrigendum: A pan-cancer proteomic perspective on The Cancer Genome Atlas.
|
Nat Commun
|
2015
|
0.76
|
|
83
|
Blasted cell line names.
|
Cancer Inform
|
2010
|
0.75
|
|
84
|
MYB-fusions and other potential actionable targets in adenoid cystic carcinoma.
|
Curr Opin Oncol
|
2016
|
0.75
|
|
85
|
Prognostic Factors as a Function of Disease-free Interval After Definitive (Chemo)radiation for Non-Small Cell Lung Cancer Using Conditional Survival Analysis.
|
Am J Clin Oncol
|
2015
|
0.75
|
|
86
|
Meeting Report: Fifth Annual AACR Frontiers in Cancer Prevention Research.
|
Cancer Res
|
2007
|
0.75
|
|
87
|
Angiogenesis inhibitors for lung cancer: clinical developments and future directions.
|
J Thorac Oncol
|
2006
|
0.75
|